SCHEMBL27093085

SCHEMBL27093085

CC(=O)Nc1ccc2nc(NC(=O)Nc3cccc(Cl)c3)sc2c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 3/20 0.72
▸ MAPT P10636 6/20 0.72
▸ KDM4E B2RXH2 5/20 0.72
▸ ALDH1A1 P00352 4/20 0.72
▸ POLB P06746 4/20 0.72
▸ MEN1 O00255 3/20 0.72
▸ KMT2A Q03164 3/20 0.72
▸ LMNA P02545 3/20 0.72
▸ HTT P42858 1/20 0.72
▸ ATM Q13315 1/20 0.72
▸ DYRK1A Q13627 2/20 0.64
▸ FSCN1 Q16658 1/20 0.64
▸ LDHA P00338 1/20 0.62
▸ RAB9A P51151 8/20 0.61
▸ DYRK1B Q9Y463 1/20 0.61
▸ KDR P35968 1/20 0.60
▸ SMN1; SMN2 Q16637 2/20 0.58
▸ NPC1 O15118 4/20 0.58
▸ PKM P14618 1/20 0.58
▸ RECQL P46063 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27093078 0.87 KDR (0.75) HSD17B10MAPTKDM4EALDH1A1POLB
SCHEMBL27093088 0.87 MEN1 (0.76) HSD17B10MAPTKDM4EALDH1A1POLB
SCHEMBL21568039 0.85 LMNA (0.70) HSD17B10MAPTKDM4EALDH1A1POLB
SCHEMBL27093081 0.85 LMNA (0.70) HSD17B10MAPTKDM4EALDH1A1POLB
SCHEMBL27093269 0.85 HSD17B10 (0.71) HSD17B10MAPTKDM4EALDH1A1POLB
SCHEMBL31206306 0.84 MAPT (0.73) MAPTKDM4EALDH1A1POLBMEN1
SCHEMBL6225459 0.84 MAPT (0.73) MAPTKDM4EALDH1A1POLBMEN1
SCHEMBL21568954 0.84 DYRK1A (0.66) HSD17B10MAPTKDM4EALDH1A1POLB
SCHEMBL21568038 0.84 KMT2A (1.00) HSD17B10MAPTKDM4EALDH1A1POLB
SCHEMBL21568341 0.83 HSD17B10 (0.72) HSD17B10MAPTKDM4EALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199562-A1 UREA DERIVATIVES FOR TREATING UVEAL MELANOMA Institut National de la Santé et de la Recherche Médicale (FR) 2024-06-20 — — US claimed
EP-4322944-A1 UREA DERIVATIVES FOR TREATING UVEAL MELANOMA Centre National de la Recherche Scientifique (FR) 2024-02-21 — — EP claimed
WO-2022219123-A1 UREA DERIVATIVES FOR TREATING UVEAL MELANOMA CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2022-10-20 — — WO claimed
US-20240199562-A1 UREA DERIVATIVES FOR TREATING UVEAL MELANOMA Institut National de la Santé et de la Recherche Médicale (FR) 2024-06-20 — — US disclosed
EP-4322944-A1 UREA DERIVATIVES FOR TREATING UVEAL MELANOMA Centre National de la Recherche Scientifique (FR) 2024-02-21 — — EP disclosed
WO-2022219123-A1 UREA DERIVATIVES FOR TREATING UVEAL MELANOMA CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2022-10-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199562-A1 UREA DERIVATIVES FOR TREATING UVEAL MELANOMA UACA, SLC14A1, MITF HSD17B10 3331/4885MAPT 409/4885KDM4E 708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback